Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature

References

• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.0000000000000630
   PubMed Web of Science ®Google Scholar
• Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–1620. doi:10.1093/annonc/mdv041
   PubMed Web of Science ®Google Scholar
• Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534. doi:10.1016/S1470-2045(17)30110-9
   PubMed Web of Science ®Google Scholar
• Linnoila RI. Functional facets of the pulmonary neuroendocrine system. Lab Invest. 2006;86(5):425–444. doi:10.1038/labinvest.3700412
   PubMed Web of Science ®Google Scholar
• Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV. The molecular basis of lung morphogenesis. Mech Dev. 2000;92(1):55–81. doi:10.1016/S0925-4773(99)00325-1
   Web of Science ®Google Scholar
• Warren WH, Memoli VA, Gould VE. Immunohistochemical and ultrastructural analysis of bronchopulmonary neuroendocrine neoplasms. I. Carcinoids. Ultrastruct Pathol. 1984;6(1):15–27. doi:10.3109/01913128409016661
   PubMed Web of Science ®Google Scholar
• Volante M, Gatti G, Papotti M. Classification of lung neuroendocrine tumors: lights and shadows. Endocrine. 2015;50(2):315–319.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29(2):179–187. doi:10.1097/01.pas.0000149690.75462.29
   PubMed Web of Science ®Google Scholar
• Rindi G, Klersy C, Inzani F, et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer. 2013;21(1):1–16. doi:10.1530/ERC-13-0246
   Web of Science ®Google Scholar
• Zahel T, Krysa S, Herpel E, et al. Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Arch. 2012;460(3):299–308. doi:10.1007/s00428-012-1194-2
   Web of Science ®Google Scholar
• Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol. 2012;25(9):1258–1264. doi:10.1038/modpathol.2012.81
   PubMed Web of Science ®Google Scholar
• Grimaldi F, Muser D, Beltrami CA, et al. Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score. Front Endocrinol (Lausanne). 2011;2:20. doi:10.3389/fendo.2011.00020
   Google Scholar
• Swarts DR, Rudelius M, Claessen SM, et al. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids. Histopathology. 2017;70(3):412–422. doi:10.1111/his.13096
   PubMed Web of Science ®Google Scholar
• Granberg D, Sundin A, Janson ET, Oberg K, Skogseid B, Westlin JE. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf). 2003;59(6):793–799. doi:10.1046/j.1365-2265.2003.01931.x
   PubMed Web of Science ®Google Scholar
• Ambrosini V, Nanni C, Zompatori M, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37(4):722–727. doi:10.1007/s00259-009-1349-9
   Web of Science ®Google Scholar
• Lococo F, Perotti G, Cardillo G, et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. Clin Nucl Med. 2015;40(3):e183–9. doi:10.1097/RLU.0000000000000641
   Web of Science ®Google Scholar
• Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology. 2014;270(2):517–525. doi:10.1148/radiol.13122501
   PubMed Web of Science ®Google Scholar
• Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43:441–452.18. doi:10.1007/s00259-015-3190-7
   PubMed Web of Science ®Google Scholar
• Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51(3):353–359. doi:10.2967/jnumed.109.066662
   Web of Science ®Google Scholar
• Baxi AJ, Chintapalli K, Katkar A, Restrepo CS, Betancourt SL, Sunnapwar A. Multimodality imaging findings in carcinoid tumors: a head-to-toe spectrum. Radiographics. 2017;37(2):516–536. doi:10.1148/rg.2017160113
   Web of Science ®Google Scholar
• Carideo L, Prosperi D, Panzuto F, et al. Role of combined [(68)Ga]Ga-DOTA-SST analogues and [(18)F]FDG PET/CT in the management of GEP-NENs: a systematic review. J Clin Med. 2019;8(7):1032. doi:10.3390/jcm8071032
   Web of Science ®Google Scholar
• Erasmus JJ, Mc Adams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170(5):1369. doi:10.2214/ajr.170.5.9574618
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lowe VJ, Aubry MC, et al. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131(1):255–260. doi:10.1378/chest.06-0711
   Web of Science ®Google Scholar
• Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. Am J Roentgenol. 2007;188(5):1223–1231. doi:10.2214/AJR.06.0503
   Web of Science ®Google Scholar
• Abgral R, Leboulleux S, Déandreis D, et al. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011;96(3):665–671. doi:10.1210/jc.2010-2022
   PubMed Web of Science ®Google Scholar
• Malczewska A, Kidd M, Matar S, et al. An assessment of circulating chromogranin A as a biomarker of bronchopulmonary neuroendocrine neoplasia: a systematic review and meta-analysis. Neuroendocrinology. 2020;110(3–4):198‐216. doi:10.1159/000500525
   Web of Science ®Google Scholar
• Robelin P, Hadoux J, Forestier J, et al. Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors. J Thorac Oncol. 2019;14(6):993–1002. doi:10.1016/j.jtho.2019.02.002
   Web of Science ®Google Scholar
• Fazio N, Ungaro A, Spada F, et al. The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. J Thorac Dis. 2017;9(Suppl 15):S1501–S1510. doi:10.21037/jtd.2017.06.14
   Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959. doi:10.1002/cncr.11105
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. doi:10.1200/JCO.2007.15.4377
   PubMed Web of Science ®Google Scholar
• Filosso PL, Ferolla P, Guerrera F, et al. Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis. 2015;7(S2):S163–S171. doi:10.3978/j.issn.2072-1439.2015.04.20
   Web of Science ®Google Scholar
• Peri M, Botteri E, Pisa E, et al. A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. J Thorac Dis. 2018;10(7):3928–3939. doi:10.21037/jtd.2018.06.78
   Web of Science ®Google Scholar
• Perez EA, Koniaris LG, Snell SE, et al. 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg. 2007;31(5):1022–1030. doi:10.1007/s00268-005-0774-6
   Web of Science ®Google Scholar
• Lou F, Sarkaria I, Pietanza C, et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg. 2013;96(4):1156–1162. doi:10.1016/j.athoracsur.2013.05.047
   Web of Science ®Google Scholar
• Öberg K, Hellman P, Ferolla P, et al. Neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up; ESMO guidelines working group. Ann Oncol. 2012;23 Suppl 7:vii120–3. doi:10.1093/annonc/mds267
   PubMed Web of Science ®Google Scholar
• Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784–798. doi:10.1097/MPA.0b013e3181ec1380
   Web of Science ®Google Scholar
• Bhosale P, Shah A, Wei W, et al. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol. 2013;23(2):400–407. doi:10.1007/s00330-012-2615-y
   Web of Science ®Google Scholar
• Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22(8):934–944. doi:10.1097/00000478-199808000-00003
   PubMed Web of Science ®Google Scholar
• Skuladottir H, Hirsch FR, Hansen HH, et al. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 2002;37(2):127–135. doi:10.1016/S0169-5002(02)00080-6
   Web of Science ®Google Scholar
• Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18(2):156–161. doi:10.1016/S1010-7940(00)00493-0
   Web of Science ®Google Scholar
• Filosso PL, Ruffini E, Di Gangi S, et al. Prognostic factors in neuroendocrine tumours of the lung: a single-centre experience. Eur J Cardiothorac Surg. 2014;45(3):521–526. doi:10.1093/ejcts/ezt442
   Web of Science ®Google Scholar
• Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg. 2004;77(5):1781–1785. doi:10.1016/j.athoracsur.2003.10.089
   Web of Science ®Google Scholar
• Rea F, Rizzardi G, Zuin A, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg. 2007;31(2):186–191. doi:10.1016/j.ejcts.2006.10.040
   PubMed Web of Science ®Google Scholar
• Filosso PL, Falcoz PE, Solidoro P, et al. ESTS lung neuroendocrine working-group participating centers*. The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database. J Thorac Dis. 2018;10(Suppl 29):S3528–S3532. doi:10.21037/jtd.2018.04.104
   Web of Science ®Google Scholar
• Forde PM, Hooker CM, Boikos SA. Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid, a brief report. J Thorac Oncol. 2014;9:414–418. doi:10.1097/JTO.0000000000000065
   Web of Science ®Google Scholar
• Asamura H, Kameya T, Matsuno Y. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24(1):70–76. doi:10.1200/JCO.2005.04.1202
   PubMed Web of Science ®Google Scholar
• Laddha SV, da Silva EM, Robzyk K, et al. Integrative genomic characterization identifies molecular subtypes of lung carcinoids. Cancer Res. 2019;79(17):4339–4347. doi:10.1158/0008-5472.CAN-19-0214
   PubMed Web of Science ®Google Scholar
• Simbolo M, Mafficini A, Sikora KO, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2017;241(4):488–500. doi:10.1002/path.4853
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014;5:3518. doi:10.1038/ncomms4518
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Minoia M, Martini C, et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer. 2010;17(3):719–729. doi:10.1677/ERC-10-0097
   Web of Science ®Google Scholar
• Righi L, Volante M, Rapa I, et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer. 2010;17(4):977–987. doi:10.1677/ERC-10-0157
   PubMed Web of Science ®Google Scholar
• Derks JL, Leblay N, Lantuejoul S, et al. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13(6):752–766. doi:10.1016/j.jtho.2018.02.002
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang M. PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours. Oncol Lett. 2017;14(2):1373–1378. doi:10.3892/ol.2017.6331
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120(8):2858–2866. doi:10.1172/JCI37539
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012;18(6):1777–1789. doi:10.1158/1078-0432.CCR-11-2123
   PubMed Web of Science ®Google Scholar
• Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98(18):10314–10319. doi:10.1073/pnas.171076798
   PubMed Web of Science ®Google Scholar
• Gagliano T, Bellio M, Gentilin E, et al. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr Relat Cancer. 2013;20(4):463–475. doi:10.1530/ERC-13-0042
   Web of Science ®Google Scholar
• Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–135. doi:10.1038/nm0202-128
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study. Lancet. 2011;378(9808):2005–2012. doi:10.1016/S0140-6736(11)61742-X
   PubMed Web of Science ®Google Scholar
• Fazio N, Granberg D, Grossman A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2013;143(4):955–962. doi:10.1378/chest.12-1108
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–977. doi:10.1016/S0140-6736(15)00817-X
   PubMed Web of Science ®Google Scholar
• Fazio N, Buzzoni R, Delle Fave G, et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018;109(1):174–181.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Fazio N, et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. 2014;120(16):2457–2463. doi:10.1002/cncr.28726
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Pusceddu S, et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: a 5-year update. Neuroendocrinology. 2018;106(4):307–311. doi:10.1159/000479587
   Web of Science ®Google Scholar
• Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, Phase 2 trial. Lancet Oncol. 2017;18(12):1652–1664.
   PubMed Web of Science ®Google Scholar
• Yao J, Garg A, Chen D, et al. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer. 2019;26(4):391‐403.
   Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523. doi:10.1056/NEJMoa1009290
   PubMed Web of Science ®Google Scholar
• Chan DL, Yao JC, Carnaghi C, et al. Systemic markers of inflammation in neuroendocrine tumors (NETs) and outcomes with everolimus: a pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; 2018 (Abstract #2115).
   Google Scholar
• Öberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31(2):202‐212. doi:10.1016/j.annonc.2019.11.003
   Web of Science ®Google Scholar
• Buzzoni R, Carnaghi C, Strosberg J, et al. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017;16(10):5013–5030. doi:10.2147/OTT.S142087
   Web of Science ®Google Scholar
• Faggiano A, Di Maio S, Mocerino C, et al. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019;66(2):417–424. doi:10.1007/s12020-019-01894-0
   PubMed Web of Science ®Google Scholar
• Panzuto F, Rinzivillo M, Fazio N, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014;19(9):966–974. doi:10.1634/theoncologist.2014-0037
   PubMed Web of Science ®Google Scholar
• Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–185. doi:10.1159/000443167
   PubMed Web of Science ®Google Scholar
• Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008;15(1):257–266. doi:10.1677/ERC-07-0202
   PubMed Web of Science ®Google Scholar
• Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17(16):2191–2205. doi:10.1080/14656566.2016.1236916
   PubMed Web of Science ®Google Scholar
• Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018;25(1):22–35. doi:10.1097/MED.0000000000000376
   Google Scholar